Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CUE
STRONG SELLCue Biopharma, Inc. · Healthcare · United States · $126M · Avg Vol: $3M/d
6
StockRankQ
20
V
28
M
32
P/E (TTM)
—
ROE
-138.5%
D/E
0.2x
Dividend %
—
Loading...
PRICE (1Y)-12.2%
SMA 50SMA 200
Close
$30.73
RSI (14)
62.4
52W High
$41.42
From 52W High
0.7%
SCORE BREAKDOWN
Quality
20
ROIC
-89.6%6.0
ROE
-138.5%5.5
GP/Assets
-2.0%8.5
Op. Margin
-94.3%17.2
FCF/Assets
-35.3%6.9
Piotroski
19.3
Int. Cover
-50.0x6.0
D/E Ratio
0.16x57.5
Current Ratio
3.57x59.7
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-5.6x25.0
P/FCF
—N/A
P/B
4.7x28.2
P/S
4.0x47.6
Div Yield
—N/A
Momentum
32
52W High %
74%N/A
RS 6M
144%N/A
SMA 50/200
1.41xN/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+89%69.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$126M
P/E (Forward)
-64.6x
Gross Margin
-2.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CUE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CUE | Cue Biopharma, Inc.(you) | $126M | 6 | STRONG SELL |
| 2592.HK | Cloudbreak Pharma Inc. | $125M | 5 | STRONG SELL |
| COYA | Coya Therapeutics, Inc. | $123M | 8 | STRONG SELL |
| GUTS | Fractyl Health, Inc. | $130M | 5 | STRONG SELL |
| PEPG | PepGen Inc. | $134M | 8 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $128M | 3 | STRONG SELL |
| CNTB | Connect Biopharma Holdings Limited | $126M | 10 | STRONG SELL |
| KLRS | Kalaris Therapeutics, Inc. | $111M | 8 | STRONG SELL |
| ONCY | Oncolytics Biotech Inc. | $114M | 9 | STRONG SELL |
| 0HIY.L | Atara Biotherapeutics, Inc. | $161M | 6 | STRONG SELL |
Peer medians: ROE -22.7% · P/E 25.2x · Gross margin 44.3%